Loading clinical trials...
Loading clinical trials...
An Open Label Study to Determine the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Subjects With Fatty Acid Oxidation Disorders (FAOD)
Conditions
Interventions
Low Dose REN001
High Dose REN001
Locations
7
United States
Children's Hospital Colorado
Aurora, Colorado, United States
Oregon Health and Science University
Portland, Oregon, United States
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Division of Medical Genetics, University Utah
Salt Lake City, Utah, United States
Neurology department, Raymond-Poincaré Teaching Hospital, Nord/Est/Ile de France Neuromuscular Reference Center
Garches, France
Start Date
April 4, 2019
Primary Completion Date
January 24, 2022
Completion Date
March 21, 2022
Last Updated
December 9, 2022
Lead Sponsor
Reneo Pharma Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions